文献速递胸部PETCT

EGFR突变状态与局限性肺腺癌代谢活性的关系及其对FDG PET/CT参数用于预后判断的影响

Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
PubMed 文献 · AJR Am J Roentgenol · 2018-03-16

该回顾性研究纳入I和II期肺腺癌患者,评估EGFR突变状态与FDG PET/CT代谢参数的关系及其对预后判断的影响。结果显示EGFR突变型肿瘤所有代谢及体积参数均显著低于野生型,且峰值标准化摄取值和总病灶糖酵解是比TNM分期更显著的预后因素,提示利用FDG PET/CT参数判断预后时需考虑EGFR突变状态。

要点

  • EGFR突变型肺腺癌的FDG PET/CT代谢及体积参数均显著低于野生型。
  • 峰值标准化摄取值和总病灶糖酵解是比TNM分期更显著的预后因素。
  • 利用FDG PET/CT参数判断预后时需考虑EGFR突变状态。

核心结论

  • EGFR突变与局限性肺腺癌FDG PET/CT低代谢活性相关,因突变型与野生型肿瘤代谢活性存在差异,使用FDG PET/CT参数判断预后时必须考虑EGFR突变状态。

研究设计与样本

  • 回顾性纳入I和II期肺腺癌患者,于初始FDG PET/CT检查时测量最大和峰值标准化摄取值、肿瘤/本底比值及代谢肿瘤体积和总病灶糖酵解等体积参数。

诊断标准与关键数值

  • EGFR突变型肺腺癌的所有代谢及体积FDG PET/CT参数值均显著低于EGFR野生型。
  • 所有参数对无复发生存期的预测均有统计学意义。
  • 多因素分析中峰值标准化摄取值和总病灶糖酵解是比TNM分期更显著的预后因素(p < 0.001)。
  • 预测无复发生存期的最佳截断值在两组间略有不同。

临床应用与阅片要点

  • 阅片及报告时应知晓EGFR突变型肺腺癌代谢活性较低,避免仅凭FDG摄取高低判断肿瘤侵袭性。
  • 利用FDG PET/CT代谢参数评估预后时需结合EGFR突变状态,因两组最佳截断值略有不同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purposes of this study were to assess the relation between epidermal growth factor receptor (EGFR) mutation status and FDG PET/CT findings and to evaluate the influence of this relation on the use of FDG PET/CT parameters to establish a prognosis in cases of localized lung adenocarcinoma.

MATERIALS AND METHODS: Patients with stage I and II lung adenocarcinomas were retrospectively enrolled. At the initial FDG PET/CT examination, maximum and peak standardized uptake, tumor-to-background ratio, and volumetric parameters of metabolic tumor volume and total lesion glycolysis were measured.

RESULTS: The values of all the metabolic and volumetric FDG PET/CT parameters were significantly lower in EGFR mutant than in EGFR wild-type lung adenocarcinomas. All parameters were statistically significant for predicting recurrence-free survival. In multivariate analyses, peak standardized uptake and total lesion glycolysis were more significant prognostic factors than was TNM stage (p < 0.001). Optimal cutoff values of parameters for predicting recurrence-free survival were slightly different between the two groups.

CONCLUSION: EGFR mutation is related to low metabolic activity of localized lung adenocarcinoma at FDG PET/CT. Because of differences in the metabolic activity of EGFR mutant and wild-type tumors, EGFR mutation status must be considered when FDG PET/CT parameters are used for prognosis.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kim YI, Paeng JC, Park YS, et al. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis. AJR Am J Roentgenol. 2018. PMID: 29547059. doi:10.2214/AJR.17.18916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。